Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes

References

• Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, Peters S, Planchard D, Smit EF, Solomon BJ, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: eSMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023:358–7. doi:10.1016/j.annonc.2022.12.013
   PubMedGoogle Scholar
• Borm FJ, Smit J, Oprea-Lager DE, Wondergem M, Haanen JBAG, Smit EF, de Langen AJ. Response prediction and evaluation using PET in patients with solid tumors treated with immunotherapy. Cancers (Basel). 2021;13:3083. doi:10.3390/cancers13123083.
   PubMed Web of Science ®Google Scholar
• Vos JL, Zuur CL, Smit LA, de Boer JP, Al-Mamgani A, van den Brekel MWM, Haanen JBAG, Vogel WV. [(18)f]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;49:2010–2022. doi:10.1007/s00259-021-05610-x.
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. The tumor-draining lymph node as an immune-privileged site. Immunol Rev. 2006;213:146–158. doi:10.1111/j.1600-065X.2006.00444.x.
   PubMed Web of Science ®Google Scholar
• van Pul KM, Fransen MF, van de Ven R, de Gruijl TD. Immunotherapy goes local: the central role of lymph nodes in driving tumor infiltration and efficacy. Front Immunol. 2021;12:643291. doi:10.3389/fimmu.2021.643291.
   PubMed Web of Science ®Google Scholar
• Bugalho A, Martins C, Silva Z, Nunes G, Mendes AS, Ferreira I, Videira PA. Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound. Tumour Biol. 2016;37:953–961. doi:10.1007/s13277-015-3885-1.
   PubMedGoogle Scholar
• Murthy V, Katzman DP, Tsay J-CJ, Bessich JL, Michaud GC, Rafeq S, Minehart J. Tumor-draining lymph nodes demonstrate a suppressive immunophenotype in patients with non-small cell lung cancer assessed by endobronchial ultrasound-guided transbronchial needle aspiration: a pilot study. Lung Cancer. 2019;137:94–99. doi:10.1016/j.lungcan.2019.08.008.
   PubMed Web of Science ®Google Scholar
• van de Ven R, Niemeijer ALN, Stam AGM, Hashemi SMS, Slockers CG, Daniels JM, Thunnissen E, Smit EF, de Gruijl TD, de Langen AJ. High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. ERJ Open Res. 2017;3:00110–2016. doi:10.1183/23120541.00110-2016.
   PubMedGoogle Scholar
• Lammertsma R, Oyen WJG, Boellaard AA, Spreeuwenberg MD, Smit EF, Hoekstra OS, Lammertsma AA. Reproducibility of tumor perfusion measurements using 15O-labeled water and PET. J Nucl Med. 2008;49:1763–1768. doi:10.2967/jnumed.108.053454.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X. New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2020;47:1127–1136. doi:10.1007/s00259-019-04500-7.
   PubMed Web of Science ®Google Scholar
• Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, van Nimwegen M, Lau SP, Latupeirissa K, Schetters S, et al. The PD-1/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell. 2020;38:685–700.e688. doi:10.1016/j.ccell.2020.09.001.
   PubMed Web of Science ®Google Scholar
• Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486–499. doi:10.1038/nri3862.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167–3175. doi:10.1200/jco.2009.26.7609.
   PubMed Web of Science ®Google Scholar
• Ding G, Shen T, Yan C, Zhang M, Wu Z, Cao L. IFN-γ down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. BMC Cancer. 2019;19:1053. doi:10.1186/s12885-019-6145-8.
   PubMed Web of Science ®Google Scholar
• Woods DM, Ramakrishnan R, Laino AS, Berglund A, Walton K, Betts BC, Weber JS. Decreased suppression and increased phosphorylated STAT3 in regulatory T cells are associated with benefit from adjuvant PD-1 blockade in resected metastatic melanoma. Clin Cancer Res. 2018;24:6236–6247. doi:10.1158/1078-0432.Ccr-18-1100.
   PubMed Web of Science ®Google Scholar
• Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, et al. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21:1346–1358. doi:10.1038/s41590-020-0769-3.
   PubMed Web of Science ®Google Scholar
• Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, et al. PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci U S A. 2019;116:9999–10008. doi:10.1073/pnas.1822001116.
   PubMed Web of Science ®Google Scholar
• Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, et al. PD-1T TILs as a predictive biomarker for clinical benefit to PD-1 blockade in patients with advanced NSCLC. Clin Cancer Res. 2022:4893–4906. doi:10.1158/1078-0432.Ccr-22-0992
   PubMed Web of Science ®Google Scholar
• Ferrari C, Santo G, Merenda N, Branca A, Mammucci P, Pizzutilo P, Gadaleta CD, Rubini G. Immune checkpoint inhibitors in advanced NSCLC: [(18)F]FDG PET/CT as a troubleshooter in treatment response. Diagnostics (Basel). 2021;11. doi:10.3390/diagnostics11091681.
   Google Scholar
• Jones HA, Cadwallader KA, White JF, Uddin M, Peters AM, Chilvers ER. Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: implications for interpretation of (18)F-FDG PET images. J Nucl Med. 2002;43:652–657.
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Bardhan K, Chatterjee P, Sari D, Liu B, Bell LN, Karoly ED, Freeman GJ, Petkova V, Seth P, et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun. 2015;6:6692. doi:10.1038/ncomms7692.
   PubMed Web of Science ®Google Scholar
• Lee S, Choi S, Kim SY, Yun MJ, Kim H-I. Potential utility of FDG PET-CT as a non-invasive tool for monitoring local immune responses. J Gastric Cancer. 2017;17:384–393. doi:10.5230/jgc.2017.17.e43.
   PubMed Web of Science ®Google Scholar
• Poggio M, Hu T, Pai C-C, Chu B, Belair CD, Chang A, Montabana E, Lang UE, Fu Q, Fong L, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177:414–427.e413. doi:10.1016/j.cell.2019.02.016.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Jin W, Xu K, Zheng X, Zhou Y, Luo M, Yan C, Zheng X, Jin E. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer. Tissue Cell. 2022;79:101941. doi:10.1016/j.tice.2022.101941.
   PubMed Web of Science ®Google Scholar
• Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick SR, Brahmer JR, Swanson SJ, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973–1985. doi:10.1056/NEJMoa2202170.
   PubMed Web of Science ®Google Scholar